New Versa HD System Tops Elekta's Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum

GENEVA, April 15, 2013 /PRNewswire/ -- ESTRO Booth #3400 – Elekta will debut its Versa HD™ system at the first major exhibition since the company introduced the advanced linear accelerator globally on March 1. The 2^nd ESTRO (European Society for Radiotherapy and Oncology) Forum convenes April 19-23 at the Palexpo convention center in Geneva.

Versa HD features high-precision beam shaping and tumor targeting, and the versatility to deliver high-volume conventional therapies, plus the most sophisticated linear accelerator-based treatments that require extreme targeting precision. Elekta will also highlight its newly redesigned Flexitron^® remote afterloading platform for brachytherapy designed to improve safety and efficiency in the brachytherapy workflow, as well as new programs to simplify the upgrade path from competitive oncology information systems (OIS) to MOSAIQ^® OIS.

"We expect great interest in Versa HD at this year's ESTRO Forum," says Ian Alexander, Elekta's Executive Vice President Region Europe, Africa, Latin America and Middle East. "Our most advanced linear accelerator was inspired by the advent of new and more sophisticated therapies that are showing great promise worldwide, combined with growing global cancer management challenges. It truly represents a unique radiotherapy solution that will impact patient health and quality of life."

"High-definition, high-speed beam shaping, combined with high dose rate delivery makes Versa HD the ideal SBRT machine," says Oscar Matzinger, M.D., radiation oncologist at Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland) and Hopital Riviera (Vevey, Switzerland). "More and more radiotherapy patients will be treated with SBRT, which now usually involves relatively long treatment times. In treating lung cancer or liver metastases, the faster we can deliver therapy the less chance for patient motion, and, in turn, the more precise therapy will be. The High Dose Rate mode of Versa HD certainly facilitates that."

Elekta will give live presentations of Versa HD at its exhibit booth (#3400) during the ESTRO Forum.

Other meeting highlights

• Redesigned Flexitron remote afterloading platform will emphasize safety and efficiency in the brachytherapy workflow, increasing the clinician's confidence that execution of all workflow steps proceed as planned. Included in the redesign are multiple novel advances that optimize the treatment delivery process.
• MOSAIQ OIS connectivity will also be demonstrated, highlighting simple programs to migrate from legacy Siemens LANTIS™ systems to MOSAIQ. MOSAIQ is in use at more than 3,000 sites, interfacing with delivery systems from a range of providers, including Elekta, Siemens, Varian, TomoTherapy, Accuray and Brainlab.
• Elekta will host a lunch symposium titled "Pioneer in Cancer Care," on April 20, from 13:15-14:30, in Room C, Lower Level. Subjects include Versa HD, VMAT, Agility™ and High Dose Rate mode, and Flexitron remote afterloading platform.

Learn more at www.elekta.com/ESTRO. 

Versa HD is not available for sale or distribution in all markets.  

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: [email protected]  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta 
Tel: +1 770-670-2447, email: [email protected] 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. 

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com. 

SOURCE Elekta